Paper39159263
The Rift Valley fever (RVF) vaccine candidate 40Fp8 shows an extreme attenuation in IFNARKO mice following intranasal inoculation.
Borrego B and 5 others. PLoS Negl Trop Dis, 2024. Cited by 3 papers, by iCite.
Cite this record
ConductScience Library. The Rift Valley fever (RVF) vaccine candidate 40Fp8 shows an extreme attenuation in IFNARKO mice following intranasal inoculation. Papers, record 39159263. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39159263
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- The Rift Valley fever (RVF) vaccine candidate 40Fp8 shows an extreme attenuation in IFNARKO mice following intranasal inoculation.
- PubMed
Topics10
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Rift Valley Fever | Major topic |
| Vaccines, Attenuated | Major topic |
| Rift Valley fever virus | Major topic |
| Viral Vaccines | Major topic |
| Administration, Intranasal | Major topic |
| Animals | |
| Mice | |
| Female | |
| Vaccination | |
| Antibodies, Viral |
Source PubMed
Grants2
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| AGL2017-83326-R | Ministerio de Ciencia e Innovación | PubMed | ||
| 10.13039/501100011033 | European Union Next Generation EU/PRTR | PubMed |
Source PubMed
References49
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 33633696 | A Hyper-Attenuated Variant of Rift Valley Fever Virus Generated by a Mutagenic Drug (Favipiravir) Unveils Potential Virulence Markers. | Front Microbiol | 2020 | https://conductscience.org/library/papers/33633696 | PubMed |
| 2 | 36173701 | Advances in Understanding Neuropathogenesis of Rift Valley Fever Virus. | Annu Rev Virol | 2022 | https://conductscience.org/library/papers/36173701 | PubMed |
| 3 | 26718688 | Safety and immunogenicity of a mutagenized, live attenuated Rift Valley fever vaccine, MP-12, in a Phase 1 dose escalation and route comparison study in humans. | Vaccine | 2016 | https://conductscience.org/library/papers/26718688 | PubMed |
| 4 | 32059491 | MVA Vectored Vaccines Encoding Rift Valley Fever Virus Glycoproteins Protect Mice against Lethal Challenge in the Absence of Neutralizing Antibody Responses. | Vaccines (Basel) | 2020 | https://conductscience.org/library/papers/32059491 | PubMed |
| 5 | 7485695 | Characterization of clone 13, a naturally attenuated avirulent isolate of Rift Valley fever virus, which is altered in the small segment. | Am J Trop Med Hyg | 1995 | https://conductscience.org/library/papers/7485695 | PubMed |
| 6 | 4045430 | Mutagen-directed attenuation of Rift Valley fever virus as a method for vaccine development. | J Gen Virol | 1985 | https://conductscience.org/library/papers/4045430 | PubMed |
| 7 | 36307416 | Immune correlates of protection following Rift Valley fever virus vaccination. | NPJ Vaccines | 2022 | https://conductscience.org/library/papers/36307416 | PubMed |
| 8 | 19335238 | Rift Valley fever virus. | J Am Vet Med Assoc | 2009 | https://conductscience.org/library/papers/19335238 | PubMed |
| 9 | 29511140 | Type I interferon receptor knockout mice as models for infection of highly pathogenic viruses with outbreak potential. | Zool Res | 2018 | https://conductscience.org/library/papers/29511140 | PubMed |
| 10 | 21188836 | Rift Valley fever virus(Bunyaviridae: Phlebovirus): an update on pathogenesis, molecular epidemiology, vectors, diagnostics and prevention. | Vet Res | 2010 | https://conductscience.org/library/papers/21188836 | PubMed |
| 11 | 20682902 | Epidemiologic and clinical aspects of a Rift Valley fever outbreak in humans in Tanzania, 2007. | Am J Trop Med Hyg | 2010 | https://conductscience.org/library/papers/20682902 | PubMed |
| 12 | 25764399 | Factors associated with severe human Rift Valley fever in Sangailu, Garissa County, Kenya. | PLoS Negl Trop Dis | 2015 | https://conductscience.org/library/papers/25764399 | PubMed |
| 13 | 12092782 | Teratogenicity of a mutagenised Rift Valley fever virus (MVP 12) in sheep. | Onderstepoort J Vet Res | 2002 | https://conductscience.org/library/papers/12092782 | PubMed |
| 14 | 33805122 | The Change P82L in the Rift Valley Fever Virus NSs Protein Confers Attenuation in Mice. | Viruses | 2021 | https://conductscience.org/library/papers/33805122 | PubMed |
| 15 | 1774469 | Recombinant human interferon-gamma modulates Rift Valley fever virus infection in the rhesus monkey. | J Interferon Res | 1991 | https://conductscience.org/library/papers/1774469 | PubMed |
| 16 | 27771072 | Mouse model for the Rift Valley fever virus MP12 strain infection. | Vet Microbiol | 2016 | https://conductscience.org/library/papers/27771072 | PubMed |
| 17 | 36122681 | Estimation of the Minimal Rift Valley Fever Virus Protective Neutralizing Antibody Titer in Human Volunteers Immunized with MP-12 Vaccine Based on Protection in a Mouse Model of Disease. | Am J Trop Med Hyg | 2022 | https://conductscience.org/library/papers/36122681 | PubMed |
| 18 | 38257787 | Safety and Efficacy upon Infection in Sheep with Rift Valley Fever Virus ZH548-rA2, a Triple Mutant Rescued Virus. | Viruses | 2024 | https://conductscience.org/library/papers/38257787 | PubMed |
| 19 | 36992291 | Perspectives of Next-Generation Live-Attenuated Rift Valley Fever Vaccines for Animal and Human Use. | Vaccines (Basel) | 2023 | https://conductscience.org/library/papers/36992291 | PubMed |
| 20 | 23593523 | Aerosol exposure to Rift Valley fever virus causes earlier and more severe neuropathology in the murine model, which has important implications for therapeutic development. | PLoS Negl Trop Dis | 2013 | https://conductscience.org/library/papers/23593523 | PubMed |
Cited by3
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 3 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42728254 | Dual-antigen AdV5 vaccines against Crimean-Congo hemorrhagic fever virus induce superior humoral and Th1-biased cellular immunity. | Sci Rep | 2026 | https://conductscience.org/library/papers/42728254 | PubMed |
| 41481750 | Attenuated viral strains of priority pathogens for potential use in controlled human infection model studies: A scoping review. | PLoS Negl Trop Dis | 2026 | https://conductscience.org/library/papers/41481750 | PubMed |
| 40883324 | The 40Fp8 vaccine strain is safe and protects pregnant ewes from a virulent RVFV challenge. | NPJ Vaccines | 2025 | https://conductscience.org/library/papers/40883324 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| IFNAR1 | 3454 | PubTator's text mining | https://conductscience.org/library/genes/3454 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39159263
GET https://conductscience.org/api/papers/v1/39159263/references?page=2